Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation

SUMMARY: No clinically important pharmacokinetic interference of alendronate occurred between a new effervescent formulation of alendronate and levothyroxine when coadministered. The combination does not materially affect levothyroxine absorption. INTRODUCTION: Concurrent treatment of osteoporosis w...

Descripción completa

Detalles Bibliográficos
Autores principales: Bone, H. G., Walter, M. A., Hurley, M. E., Epstein, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393287/
https://www.ncbi.nlm.nih.gov/pubmed/28204953
http://dx.doi.org/10.1007/s00198-017-3941-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393287/
https://www.ncbi.nlm.nih.gov/pubmed/28204953
http://dx.doi.org/10.1007/s00198-017-3941-3

Ejemplares similares